Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy
Leuk Lymphoma. 2023 Aug 25:1-4.
doi: 10.1080/10428194.2023.2247511.
Online ahead of print.